In rodent models of AD, Singh and colleagues found that guanabenz treatment provided substantial protection against AD-specific behavioral and pathological markers, including alterations in acetylcholinesterase activity, tau phosphorylation, amyloid precursor protein processing, and memory retention [159]. This evidence concerns the gene APP and Alzheimer disease.